The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Advances in treating amyloidosis with botulinum toxin
Maria Moscvin, MD, Brigham and Women’s Hospital, Boston, MA, describes the next steps in assessing botulinum neurotoxin as a treatment for amyloidosis, which targets immunoglobulin free light chains (FLC). Further research is required in in vivo models and developing a hydrogel scaffold coated with stromal cells will enable to mimic the microenvironment of amyloidosis cells. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
